Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS - Seite 3

Nachrichtenquelle: globenewswire
19.11.2020, 15:00  |  116   |  0   |   

Diesen Artikel teilen
Seite 3 von 2
Wertpapier


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS - Seite 3 - Data support confidence in SPEARHEAD-1 as a registrational trial - - Projected to complete recruitment of all patients in Q1 2021 - - Median duration of response was 28 weeks with ongoing responses beyond 72 weeks in two patients; median overall …

Community

Nachrichten des Autors

Titel
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their ...
Titel
Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million
Emerging Markets Report: Expand the Brand
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results ...
Hunter Technology Market Testing Pilot April Launch
Algernon Pharmaceuticals Announces Private Placement
Bitfarms Announces Purchase Agreement for 48,000 MicroBT Miners to Expand Hash Rate Capacity by ...
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in ...
BIGG Digital Assets Inc. Announces Grant of Stock Options
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital ...
3D Systems Reports Fourth Quarter and Full Year 2020 Financial Results (Unaudited), Reschedules ...
Titel
Spineway Expansion in Asia
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to ...
SPINEWAY: NEW BUSINESS AGREEMENT DEDICATED TO 3D INNOVATION
American Lithium Reaches Agreement to Acquire Plateau Energy Metals and Consolidate ...
REPEAT --TAAT E-Commerce Launching Wednesday February 17, Availing Original, Smooth, and Menthol to ...
Emerging Markets Report: One + One = Three
Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
EHang Responds to Deceptive Wolfpack Research Report
Seeking Alpha Blog Post Details Growth of Alternatives to Incumbent CPG Products in February 11 ...
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product ...
Titel
Spineway Expansion in Asia
AgraFlora Organics Expects to Enter Edibles Market in Q1
HyperSolar Changes Company Name to SunHydrogen
Halo Announces Pricing of Overnight Marketed Offering of Units
WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020
Bombardier unterzeichnet Vertrag für weitere zehn Jahre Betrieb und Wartung des automatischen ...
Ocugen and Bharat Biotech to Co-Develop COVAXIN, a Whole-Virion Inactivated COVID-19 Vaccine, for ...
HyperSolar To Begin Production on 100 Hydrogen Generation Units for Demonstration
Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of ...

Nachrichten zu den Werten

ZeitTitel
25.02.21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
11.02.21
Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021

COMMUNITY

ZeitTitel
25.02.21
49
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived A